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Abstract: Cancer is one of the most extreme medical conditions in both developing and developed
countries around the world, causing millions of deaths each year. Chemotherapy and/or radiotherapy
are key for treatment approaches, but both have numerous adverse health effects. Furthermore,
the resistance of cancerous cells to anticancer medication leads to treatment failure. The rising burden
of cancer overall requires novel efficacious treatment modalities. Natural medications offer feasible
alternative options against malignancy in contrast to western medication. Furanocoumarins’ defensive
and restorative impacts have been observed in leukemia, glioma, breast, lung, renal, liver, colon,
cervical, ovarian, and prostate malignancies. Experimental findings have shown that furanocoumarins
activate multiple signaling pathways, leading to apoptosis, autophagy, antioxidant, antimetastatic,
and cell cycle arrest in malignant cells. Additionally, furanocoumarins have been shown to have
chemo preventive and chemotherapeutic synergistic potential when used in combination with other
anticancer drugs. Here, we address different pathways which are activated by furanocoumarins and
their therapeutic efficacy in various tumors. Ideally, this review will trigger interest in furanocoumarins
and their potential efficacy and safety as a cancer lessening agents.
Keywords: furanocoumarin; apoptosis; autophagy; metastasis; cell cycle arrest
1. Introduction
Cancer exacts one of the greatest medical tolls on humankind, requiring a proactive procedure for
prevention and treatment. An enormous number of patients succumb to cancer every year. It is one of
the chief reasons for mortality around the world, and the number of cases is continually expanding
and estimated to reach 21 million by 2030. The lack of efficient anticancer treatments remains a clinical
problem [1,2]. Chemotherapy and/or radiotherapy are the main clinical approaches to cancer treatment,
yet both have documented adverse effects [3–6]. Cancer treatment affects not only rapidly multiplying
cancerous cells but also normal body cells (bone marrow, gastrointestinal tract (GIT), and hair follicles);
therefore, these treatments may give rise to severe adverse symptoms. Moreover, quick disposal and
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widespread distribution of the medications in cancer-free organs requires high dosing, which may lead
to incremental adverse reactions. Resistance towards malignant growth is another restriction.
Restorative plants have been utilized previously. Phytopharmaceuticals primarily target malignant
growth, and hence, they are the most appropriate contender for anticancer medications [1,2]. Nowadays,
significant efforts have improved the efficacy of natural anticancer drugs with the appearance of
encouraging strategies [7,8].
Furanocoumarins are phytochemicals that have been utilized for quite a while. The Atharva-Veda,
the Indian hallowed book, portrays the Psoralea corylifolia poultice, and the old Egyptians utilized Ammi
majus for leukoderma (vitiligo). In 1838, 5-Methoxypsoralen (5-MOP) was the first furanocoumarin
isolated from Citrus bergamia oil by Kalbrunner [9]. Furocoumarins are formed by coumarin and a furan
ring combination, resulting in angular or linear isomers depending on the furan ring position. Angelicin
and psoralen are basic furocoumarins that act as precursors for angular and linear furocoumarins,
respectively. These compounds are, for the most part, biosynthesized by phenylpropanoid and
the mevalonic pathways. Furocoumarins are produced in plants of Apiaceae and Rutaceae as
well as in Asteraceae, Caryophyllaccae, Fabaceae, Moraceae, and Salvadoraceae for defense against
insects, bacterial and fungal predators. They provide antimicrobial and insecticidal activity and
behave as natural pesticides [10]. Furocoumarins have promising therapeutic prospects, such as
analgesic, anticonvulsive, anticoagulant, hypotensive, antidepressants, antibacterial, antifungal,
antiviral, anti-inflammatory, antiallergic [11,12], antioxidants [13], and inhibitors of human carbonic
anhydrase isozymes [14], against skin diseases [15,16], hyperproliferative disorders [17,18] and as an
anticancer [19]. This review is aimed at evaluating the literature on the anticancer potential of various
furanocoumarins through different underlying mechanisms and thereof therapeutic/clinical status.
2. Chemistry of Furocoumarins
The exact molecular mechanism of such an activity relies upon the chemical structure of
furanocoumarins, which depends on the furan ring and coumarin backbone combination in an
angular or linear structure just as the type, location, and the number of the substituents attached [11].
The CH3 presence at C5 improves the tumor properties of psoralen and 5-MOP, paying little heed to the
substituent location. The substitution of the methoxy group with an isopentenyloxy moiety in the C5
position prompted abatement in the pro-apoptotic properties of the compound [20–22]. Angelicin is the
most straightforward angular furanocoumarin and it displays counter cancer properties. Analogous to
linear furocoumarins, angular analogs can be substituted with a methoxy or isopentenyloxy group.
Methoxy subordinates of angelicin incorporate isobergapten and sphondin. Isobergapten, for example,
5-methoxyangelicine, is a linear isomer of bergapten with a methoxy group joined to the fifth (C5)
carbon atom. Thus, sphondin (6-methoxyangelicin) can be considered as an angular analogue of
xanthotoxin. The thing that matters is, be that as it may, that the methoxy group is appended to the C6
position in 6-methoxyangelicin and to the C8 atom in the 8-MOP [11].
Furanocoumarins’ defensive and restorative properties have been observed in leukemia, glioma,
breast, lung, renal, liver, colon, cervical, ovarian, and prostate malignancies. Apoptosis, autophagy,
antioxidant, cell cycle capture, Nuclear Factor Kappa-light-chain-enhancer of activated B cells
(NF-κB) inactivation, Phosphatidylinositol 3-kinase/RAC-α Serine/Threonine-Protein Kinase (PI3K/Akt)
inhibition, and p53 modulation incorporate mechanistic insight (Table 1; Figure 1). In this article,
we have reviewed the experimental data showed the role of furanocoumarins for cancer prevention
and treatment.
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Table 1. Anticancer effects of furanocoumarins in the different reported studies.
Furanocoumarins Dietary Sources [2–4]
In Vitro In Vivo
Anticancer Mechanisms References
Cell Lines Cytotoxic Concentration Experimental Model Dose
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HeLa and SiHa 
IC30 = 27.8 µM; IC50 = 
38.2 µM 
— — Atg3,7 and 12-5 ↑, G1/G0 arrest [5] 
A549 (NSCLC) IC50~ 50 µmol — — 
NF-κB inactivation G2/M phase arrest, 
cyclinB1 ↓, cyclin E1 ↓, andCdc2 ↓; Bcl2 ↓; 
caspase 3,9 ↑, Bax↑ 
JNK ↑, ERK ↑; 
MMP2,MMP9 ↓, E-cadherin ↑ 
[6] 
SH-SY5Y IC50 = 49.56µM — — caspase 3,9 ↑, Bcl-2 ↓, Bcl-xL↓, and Mcl-1↓ [7] 
Caki 
IC50 = angelicin (50–100 
µM) and TRAIL (50 
ng/mL) 
— — caspase 3↑, c-FLIP ↓ [8] 
HepG2 and 
Huh-7 
IC50 = 90 ± 6.565 
(HepG2); 60 ± 4.256 µM 
(Huh-7) 


















A549, H1299 IC50 = 50–100 µM — — 
EMT inhibition, JNK ↑; PI3K ↓, Akt↓, and 
mTOR kinases ↓ 
[10] 
U87 and U251 IC50 = 2–10 µM — — 
NF-κB inactivation, MMP9 ↓, STAT3 
inhibition, Rac1 inactivation 
[11] 
HT-1080 IC50 = 5–50 µM — — NF-κB inactivation; MMP2,MMP9↓ [12] 
HT-29 and RKO IC50 = 12.5 µM — — 
caspase-3,8,9↑; PARP ↑; 
G2/M phase arrest, cyclinA ↓, cyclin B1↓, 
andCdc2 ↓ 
[13] 
A549 (NSCLC) IC50 = 50 µM — — 






(BALB/c nude mice) 
100 mg/kg 
(18 days) 












DLD-1 and LoVo IC50 = 30 and 50 µM — — 
G2/M phase arrest,cyclin E ↓, Cdk2 
inhibition; AKT inhibition; p53 ↑, p21↑, 
PTEN↑ 
[15] 
MCF-7 IC50 = 50 µM — — 




IC50 = 25–50 mM — — G2/M phase arrest, Cdk1 inhibition [17] 
IC50 = 25–100µM — — G2-M phase arrest, P53 ↑ and P21 ↑ [18] 
A549 (NSCLC) 
79.1 ± 2.8% 
(50 µM) 
— — G1-phase arrest, P53 ↑ [19] 
Angelicin
Parsnip
HeLa and SiHa IC30 = 27.8 µM; IC50 = 38.2 µM — — Atg3,7 and 12-5 ↑, G1/G0 arrest [5]
A549 (NSCLC) IC50~ 50 µmol — —
NF-κB inactivation G2/M phase arrest,
cyclinB1 ↓, cyclin E1 ↓, and Cdc2 ↓; Bcl2 ↓;
caspase 3,9 ↑, Bax↑
JNK ↑, ERK ↑;
MMP2, MMP9 ↓, E-cadherin ↑
[6]
SH-SY5Y IC50 = 49.56 µM — — caspase 3,9 ↑, Bcl-2 ↓, Bcl-xL↓, and Mcl-1↓ [7]
Caki IC50 = angelicin (50–100 µM)and TRAIL (50 ng/mL) — — caspase 3↑, c-FLIP ↓ [8]
HepG2 and Huh-7 IC50 = 90 ± 6.565 (HepG2);60 ± 4.256 µM (Huh-7) — — PI3K/Akt inhibition, Bcl-2↓ [9]
— — Mouse liver xenograftmodel (BALB/c-nu/nu mice) 50 mg/kg (16 days)
cancer cell growth ↓;
p-VEGFR ↓ [9]
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cumin, di l, fig, 
grapefruit, lemon, 
lime, or nge, 
parsley, parsnip, 
turnip 
DLD-1 and LoVo IC50 = 30 and 50 µM — — 
G2/M phase arrest,cyclin E ↓, Cdk2 
inhibition; AKT inhibition; p53 ↑, p21↑, 
PTEN↑ 
[15] 
MCF-7 IC50 = 50 µM — — 




I 50 = 25–50 m    /   t, Cdk1 i hibition [ 7] 
IC50 = 25–100µM — — G2-M phase arrest, P53 ↑ and P21 ↑ [18] 
A549 (NSCLC) 
79.1 ± 2.8% 
(50 µM) 
— — G1-phase arrest, P53 ↑ [19] 
Bergamottin
Carrot, cumin, dill, fig,
grapefruit, lemon, lime,
orange, parsley, parsnip
A549, H1299 IC50 = 50–100µM — —
EMT inhibition, JNK ↑; PI3K ↓, Akt↓,
and mTOR kinases ↓ [10]
U87 and U251 IC50 = 2–10 µM — —
NF-κB inactivation, MMP9 ↓, STAT3
inhibition, Rac1 inactivation [11]
HT-1080 IC50 = 5–50µM — — NF-κB inactivation; MMP2, MMP9↓ [12]
HT-29 and RKO IC50 = 12.5 µM — —
caspase-3,8,9↑; PARP ↑;
G2/M phase arrest, cyclinA ↓, cyclin B1↓,
and Cdc2 ↓
[13]
A549 (NSCLC) IC50 = 50µM — —
G2/M phase arrest, cyclinA ↓, cyclin B1↓,
and Cdc2 ↓ [14]
— — Mouse lung x nograftmodel (BALB/c ude mice) 100 mg/kg (18 days) ↓ cancer cell growth [14]
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MCF-7 IC50 = 50 µM — — 




IC50 = 25–50 mM — — G2/M phase arrest, Cdk1 inhibition [17] 
IC50 = 25–100µM — — G2-M phase arrest, P53 ↑ and P21 ↑ [18] 
A549 (NSCLC) 
79.1 ± 2.8% 
(50 µM) 





cumin, dill, fig, grapefruit,
lemon, lime, orange, parsley,
parsnip, turnip
DLD-1 and LoVo IC50 = 30 and 50 µM — —
G2/M phase arrest, cyclin E ↓, Cdk2
inhibition; AKT inhibition; p53 ↑, p21↑,
PTEN↑
[15]
MCF-7 IC50 = 50 µM — —
G1-phase phase arrest, P53 ↑;
AKT inhibition [16]
Hep-G2
IC50 = 25–50 mM — — G2/M phase arrest, Cdk1 inhibition [17]
IC50 = 25–100 µM — — G2-M phase arrest, P53 ↑ and P21 ↑ [18]
A549 (NSCLC) 79.1 ± 2.8%(50 µM) — —
G1-phase arrest, P53 ↑ [19]
NCI-H460 74.5 ± 3.1%(50 µM) — —
MCF7 and ZR-75 50 µM — — PTEN ↑, Beclin1 ↑, PI3KIII ↑, UVRAG ↑,AMBRA, LC3-I to LC3-II [20]
HepG2 50 mM — — PI3K/AKT inhibition, LXR (α and β)↑
[21]
— — NDEA induced liver cancer(Wistar rats)
25 and 50 mg/kg (14
days) ↓ cancer cell growth
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Table 1. Cont.
Furanocoumarins Dietary Sources [2–4]
In Vitro In Vivo
Anticancer Mechanisms References
Cell Lines Cytotoxic Concentration Experimental Model Dose
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MCF-7 IC50 = 52.2 µM — — 
G1-phase arrest; caspase 3,9 ↑, Bax↑, Bcl2 






















HCT-15 IC50 = 18.1 ± 0.3 µg·mL−1 — — 
↓ cell viability [23] 
A549 (NSCLC) IC50 =14.3 ± 0.2 µg·mL−1 — — 
SK-OV-3 IC50 = 20.2 ± 0.3 µg·mL−1 — — 
SK-MEL-2 IC50 = 21.2 ± 0.3 µg·mL−1 — — 
XF498 IC50 = 28.4 ± 0.3 µg·mL−1 — — 
Bergaptol
Carrot, grapefruit, lemon,
lime, parsley, parsnip MCF-7 IC50 = 52.2 µM — —
G1-phase arrest; caspase 3,9 ↑, Bax↑, Bcl2
↓,MMP2 ↓, MMP9 ↓, cyt c release ↑ [22]
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A549 0.25 mM — — 
NF-κB inactivation 
Atg5 ↑, Beclin1 ↑, mTOR inactivation 















A549 IC50 = 65.28 ± 5.36 µM — — P53 ↑,Bax↑, Bcl2 ↓,caspase 3 ↑ [25] 
Cnidicin
Lemon
HCT-15 IC50 = 7.0 ± 0.2 µg·mL−1 — —
↓ cell viability [23]
A549 (NSCLC) IC50 = 6.8 ± 0.1 µg·mL−1 — —
SK-OV-3 IC50 = 8.8 ± 0.2 µg·mL−1 — —
SK-MEL-2 IC50 = 8.8 ± 0.2 µg·mL−1 — —
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A549 IC50 = 65.28 ± 5.36 µM — — P53 ↑,Bax↑, Bcl2 ↓,caspase 3 ↑ [25] 
Feroniellin A
Feroniella lucida roots A549 0.25 mM — —
NF-κB inactivation
Atg5 ↑, Beclin1 ↑, mTOR inactivation
LC3-I to LC3-II
[24]
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mTOR↓, p70S6K ↓, 4E-BP1↓, MAPK↓, 
HIF-1α inhibition 
[31] 
HCT-15 IC50 = 19.4 ± 0.3 µg·mL−1 — — 
↓ cell viability [23] 
A54  IC50 = 16.4 ± 0.3 µg·mL−1 — — 
SK-OV-3 IC50 =13.7 ± 0.3 µg·mL−1 — — 
SK-MEL-2 IC50 = 14.5 ± 0.2 µg·mL−1 — — 











G1-phase arrest; caspase 3,9 ↑; Bax↑, Bcl2 
↓,Survivin↓ 
[32] 
DU145 100 µM G1-phase arrest [33] 
HCT-15 IC50 = 5.6 ± 0.3 µg·mL−1 — — 
↓ cell viability [23] 
A549 (NSCLC) IC50 = 12.2 ± 0.4 µg·mL−1 — — 
SK-OV-3 IC50 = 6.8 ± 0.3 µg·mL−1 — — 
SK-MEL-2 IC50 = 9.9 ± 0.2 µg·mL−1 — — 





U937 IC50 = 40 µM Mice 
30mg/kg 
(30 days) 















HepG2 100 µM — — 
B x/Bcl-2 ratio ↑, MMP2 ↓,MMP9 
↓,ERK1/2 p thway inhibition, cyt c 




IC50 = 56.3 µM for 
SK-N-AS and 88.5 µM 
for SW620 
— — 
Caspase-3,8,9↑PI3K/AKT pathway ↓, Bcl2 




SGC-7901 IC50 = 18.75 µg·mL−1
SGC-7901 cell-induced
xenograft model (mice) 10 mg/kg (20 days)
G1-phase arrest; caspase 3,9 ↑; Bax↑,
Bcl2 ↓, Survivin↓ [32]
DU145 100 µM — — G1-phase arrest [33]
HCT-15 IC50 = 5.6 ± 0.3 µg·mL−1 — —
↓ cell viability [23]
A549 (NSCLC) IC50 = 12.2 ± 0.4 µg·mL−1 — —
SK-OV-3 IC50 = 6.8 ± 0.3 µg·mL−1 — —
SK-MEL-2 IC50 = 9.9 ± 0.2 µg·mL−1 — —
XF498 IC50 = 10.7 ± 0.3 µg·mL−1 — —





SGC-7901 IC50 = 62.6 µM — — 
promoting G1-phase arrest; 
PI3K/Akt/m-TOR signaling ↓ 
[26] 
HT-29 IC50 = 78 µM — — 
G1-phase arrest; P53 ↑ and P21 ↑; caspase 
3,7 ↑; Bcl2 ↓ 
[27] 
L-60 10 µM — — 
caspase 3,9 ↑; cyt c release ↑; Bcl2 ↓,PARP 
cleavage 
[28] 
H23 10 µg/mL — — P53 ↑,Bax↑, Mcl-1↓ [29] 
HeLa 
200 µM for imperatorin 
and 5 µM for cisplatin 
— — Hsp27 and Hsp72 ↓,LC3 cleavage [30] 
HCT116 150 µM   
mTOR↓, p70S6K ↓, 4E-BP1↓, MAPK↓, 
HIF-1α inhibition 
[31] 
HCT-15 IC50 = 19.4 ± 0.3 µg·mL−1 — — 
↓ cell viability [23] 
A549 IC50 = 16.4 ± 0.3 µg·mL−1 — — 
SK-OV-3 IC50 =13.7 ± 0.3 µg·mL−1 — — 
SK-MEL-2 IC50 = 14.5 ± 0.2 µg·mL−1 — — 











G1-phase arrest; caspase 3,9 ↑; Bax↑, Bcl2 
↓,Survivin↓ 
[32] 
DU145 100 µM — — G1-phase arrest [33] 
HCT-15 IC50 = 5.6 ± 0.3 µg·mL−1 — — 
↓ cell viability [23] 
A549 (NSCLC) IC50 = 12.2 ± 0.4 µg·mL−1 — — 
SK-OV-3 IC50 = 6.8 ± 0.3 µg·mL−1 — — 
SK-MEL-2 IC50 = 9.9 ± 0.2 µg·mL−1 — — 





U937 IC50 = 40 µM Mice 
30mg/kg 
(30 days) 









Ani e, carrot, 
caraway celeriac, 




HepG2 100 µM — — 
Bax/Bcl-2 ratio ↑, MMP2 ↓,MMP9 
↓,ERK1/2 pathway inhibition, cyt c 




IC50 = 56.3 µM for 
SK-N-AS and 88.5 µM 
for SW620 
— — 
Caspase-3,8,9↑PI3K/AKT pathway ↓, Bcl2 
↓,Bax/Bcl-2 ratio ↑ 
[36] 
Marmesin
Bro d bean, blackberry,
raspberry U937 IC50 = 40 µM Mice 30mg/kg (30 days)
Bax↑, Bcl2 ↓, Bax/Bcl-2 ratio ↑;
G2/M-phase arrest [34]
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SGC-7901 IC50 = 62.6 µM — — 
promoting G1-phase arrest; 
PI3K/Akt/m-TOR signaling ↓ 
[26] 
HT-29 IC50 = 78 µM — — 
G1-phase arrest; P53 ↑ and P21 ↑; caspase 
3,7 ↑; Bcl2 ↓ 
[27] 
HL-60 10 µM — — 
caspase 3,9 ↑; cyt c release ↑; Bcl2 ↓,PARP 
cleavage 
[28] 
H23 10 µg/mL — — P53 ↑,Bax↑, Mcl-1↓ [29] 
HeLa 
200 µM for imperatorin 
and 5 µM for cisplatin 
— — Hsp27 and Hsp72 ↓,LC3 cleavage [30] 
HCT116 150 µM   
mTOR↓, p70S6K ↓, 4E-BP1↓, MAPK↓, 
HIF-1α inhibition 
[31] 
HCT-15 IC50 = 19.4 ± 0.3 µg·mL−1 — — 
↓ cell viability [23] 
A549 IC50 = 16.4 ± 0.3 µg·mL−1 — — 
SK-OV-3 IC50 =13.7 ± 0.3 µg·mL−1 — — 
SK-MEL-2 IC50 = 14.5 ± 0.2 µg·mL−1 — — 











G1-phase arrest; caspase 3,9 ↑; Bax↑, Bcl2 
↓,Survivin↓ 
[32] 
DU145 100 µM — — G1-phase arrest [33] 
HCT-15 IC50 = 5.6 ± 0.3 µg·mL−1 — — 
↓ cell viability [23] 
A549 (NSCLC) IC50 = 12.2 ± 0.4 µg·mL−1 — — 
SK-OV-3 IC50 = 6.8 ± 0.3 µg·mL−1 — — 
SK-MEL-2 IC50 = 9.9 ± 0.2 µg·mL−1 — — 





U937 IC50 = 40 µM Mice 
30mg/kg 
(30 days) 















HepG2 100 µM — — 
Bax/Bcl-2 ratio ↑, MMP2 ↓,MMP9 
↓,ERK1/2 pathway inhibition, cyt c 




IC50 = 56.3 µM for 
SK-N-AS and 88.5 µM 
for SW620 
— — 
Caspase-3,8,9↑PI3K/AKT pathway ↓, Bcl2 




celeriac, celery, cumin, dill,
grapefruit, lemon, lime,
parsley, parsnip, turnip
HepG2 100 µM — —
Bax/Bcl-2 ratio ↑, MMP2 ↓, MMP9 ↓,
ERK1/2 pathway inhibition, cyt c




IC50 = 56.3 µM for SK-N-AS
and 88.5 µM for SW620 — —
Caspase-3,8,9↑PI3K/AKT pathway ↓,







IC50 = 40.33  ±  0.63 µM — — caspase 3,9 ↑; cyt c release ↑; Bcl2 ↓ [37] 
HCT-15 IC50 = 3.4 ± 0.3 µg·mL−1 — — 
↓ cell viability [23] 
A549 (NSCLC) IC50 = 9.5 ± 0.3 µg·mL−1 — — 
SK-OV-3 IC50 = 19.3 ± 0.3 µg·mL−1 — — 
SK-MEL-2 IC50 = 16.5 ± 0.2 µg·mL−1 — — 

















KBv200 75.3% (80 µg·mL−1) — — NF-κB inactivation G1/S phase arrest, 
c-FLIP,and IAP inhibition 
[38] 




— — G1/G0 phase arrest [39] 
SMMC7721 40 µM — — 
G1 phase arrest, cyclin E↓, Bax↑, Bcl2 ↓, 





IC10 = 8 µg/mL   P-gp efflux function inhibition [41] 
IC50 = 25.59 ± 1.74 
 µg/mL 
  P-gp ATPase activity inhibition 
[42] 
43.0  µM   EMT inhibition 
107.5  µM   G0/G1 phase arrest 
 
Sphondin 




Lime SW480 25 µM (67%) — — 
caspase-3,8↑; Bcl2 ↓; p38 MAPK 








IC50 = 40.33 ± 0.63 µM — — caspase 3,9 ↑; cyt c release ↑; Bcl2 ↓ [37]
HCT-15 IC50 = 3.4± 0.3 µg·mL−1 — —
↓ cell viability [23]
A549 (NSCLC) IC50 = 9.5 ± 0.3 µg·mL−1 — —
SK-OV-3 IC50 = 19.3 ± 0.3 µg·mL−1 — —
SK-MEL-2 IC50 = 16.5 ± 0.2 µg·mL−1 — —
XF498 IC50 = 16.1 ± 0.5 µg·mL−1 — —







IC50 = 40.33  ±  0.63 µM   caspase 3,9 ↑; cyt c release ↑; Bcl2 ↓ [37] 
HCT-15 IC50 = 3.4 ± 0.3 µg·mL−1   
↓ cell viability [23] 
A549 (NSCLC) IC50 = 9.5 ± 0.3 µg· L−1   
SK-OV-3 I 50 = 19.3 ± 0.3 g· L−1   
SK-MEL-2 IC50 = 16.5 ± 0.2 µg·mL−1 — — 

















KBv200 75.3% (80 µg·mL−1) — — NF-κB inactivation G1/S phase arrest, 
c-FLIP,and IAP inhibition 
[38] 




— — G1/G0 phase arrest [39] 
SMMC7721 40 µM — — 
G1 phase arrest, cyclin E↓, Bax↑, Bcl2 ↓, 





IC10 = 8 µg/mL   P-gp efflux function inhibition [41] 
IC50 = 25.59 ± 1.74 
 µg/mL 
  P-gp ATPase activity inhibition 
[42] 
43.0  µM   EMT inhibition 
107.5  µM   G0/G1 phase arrest 
 
Sphondin 




Lime SW480 25 µM (67%) — — 
caspase-3,8↑; Bcl2 ↓; p38 MAPK 








IC50 > 30 µg·mL−1 — —







I 50 = 40.33  ±  0.63 µM   caspase 3,9 ↑; cyt c release ↑; Bcl2 ↓ [37] 
HCT-15 I 50 = 3 4    .  · −1   
↓ cell viability [23] 
A549 (NSCLC) IC50 = .5  .  · −1   
SK-OV-3 I 50  9.3  .3 · −1   
SK-MEL-2 I 50  .5  .2 · −1   








IC50 > 30 µg·mL−1 — — 
 
Psoralen 
Car ot, celeriac, 
elery cilantro, 




KBv200 75.3  (  · −1)   NF-κB inactivation G1/S phase arrest, 
c-FLIP,and IAP inhibition 
[38] 




  G1/G0 phase arrest [39] 
SMMC7721 40 µM — — 
G1 phase arre t, cyclin E↓, Bax↑, Bcl2 ↓, 
ER stress, CHOP induction, 




IC10 = 8 g/mL   P-gp efflux fu ction i hibition [41] 
IC50 = 2 .59 ± 1.74 
 µg/mL 
  P-gp ATPase activity inhibition 
[42] 
43.0      EMT inhibition 
107.5  µM   G0/G1 phase arrest 
 
Sphondin 




Lime SW480 25 µM (67%) — — 
caspase-3,8↑; Bcl2 ↓; p38 MAPK 





cilantr , cumin, dill, fig,
grapefruit, lemon, lime,
parsley, parsnip
KBv200 75.3% (80 µg·mL−1) — — NF-κB inactivation G1/S phase arrest,
c-FLIP, and IAP inhibition
[38]
K562 92.4% (80 µg·mL−1) — —
MCF-7 17.32± 4.28% (8µg·mL−1) — — G1/G0 phase arrest [39]
SMMC7721 40 µM — —
G1 phase arrest, cyclin E↓, Bax↑, Bcl2 ↓,





IC10 = 8 µg/mL P-gp efflux function inhibition [41]
IC50 = 25.59 ± 1.74 µg/mL P-gp ATPase activity inhibition
[42]43.0 µM EMT inhibition
107.5 µM G0/G1 phase arrest
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IC50 = 40.33  ±  0.63 µM — — caspase 3,9 ↑; cyt c release ↑; Bcl2 ↓ [37] 
HCT-15 IC50 = 3.4 ± 0.3 µg·mL−1 — — 
↓ cell viability [23] 
A549 (NSCLC) IC50 = 9.5 ± 0.3 µg·mL−1 — — 
SK-OV-3 IC50 = 19.3 ± 0.3 µg·mL−1 — — 
SK-MEL-2 IC50 = 16.5 ± 0.2 µg·mL−1 — — 

















KBv200 75.3% (80 µg·mL−1) — — NF-κB inactivation G1/S phase arrest, 
c-FLIP,and IAP inhibition 
[38] 




— — G1/G0 phase arrest [39] 
SMMC7721 40 µM — — 
G1 phase arrest, cyclin E↓, Bax↑, Bcl2 ↓, 





IC10 = 8 µg/mL   P-gp efflux function inhibition [41] 
IC50 = 25.59 ± 1.74 
 µg/mL 
  P-gp ATPase activity inhibition 
[42] 
43.0  µM   EMT inhibition 
107.5  µM   G0/G1 phase arrest 
 
Sphondin 




Lime SW480 25 µM (67%) — — 
caspase-3,8↑; Bcl2 ↓; p38 MAPK 




Parsnip A549 50 µM — — NF-κB inactivation [43]







IC50 = 40.33  ±  0.63 µM — — caspase 3,9 ↑; cyt c release ↑; Bcl2 ↓ [37] 
HCT-15 IC50 = 3.4 ± 0.3 µg· L−1   
↓ cell viability [23] 
A549 (NSCLC) IC50 = 9.5 ± 0.3 µg· L−1   
SK-OV-3 IC50 = 19.3 ± 0.3 µg· L−1   
SK-MEL-2 IC50 = 16.5 ± 0.2 µg· L−1   

















KBv200 75.3  (80 µg· L−1)   NF-κB inactivation G1/S phase arrest, 
c-FLIP,and IAP inhibition 
[38] 




— — G1/G0 phase arrest [39] 
SMMC7721 40 µM — — 
G1 phase arrest, cyclin E↓, Bax↑, Bcl2 ↓, 





IC10 = 8 µg/mL   P-gp efflux function inhibition [41] 
IC50 = 25.59 ± 1.74 
 µg/mL 
  P-gp ATPase activity inhibition 
[42] 
43.0  µ    EMT inhibition 
107.5  µM   G0/G1 phase arrest 
 
Sphondin 




Lime SW480 25 µM (67%) — — 
caspase-3,8↑; Bcl2 ↓; p38 MAPK 




Lime SW480 25 µM (67%) — —




Human cancer cell lines: A549 (NSCLC), NCI-H460 (NSCLC), H23, and H1299 = lung cancer; Caki = renal carcinoma; DLD-1, LoVo, HCT-15, HT-29, HCT116, RKO, SW480 and
SW620 = colorectal cancer; DU145 = prostate cancer; HL-60 = promyelocytic leukemia; HeLa and SiHa = cervical cancer; HepG2, Huh-7 and SMMC7721 = liver carcinoma;
HT-1080 = fibrosarcoma; KBM-5, K562 = human chronic myeloid leukaemia; KBv200 = oral squamous carcinoma; MCF7 SKBR-3 and ZR-75 = breast cancer; SH-SY5Y and
SK-N-AS = neuroblastoma; SK-MEL-2 = melanoma; SK-OV-3 = ovarian cancer; SGC-7901 = gastric cancer cell; U937 = leukemia; U87 and U251 = glioma cells; XF498 = CNS solid tumor;
MCF-7/ADR = doxorubicin resistant derivatives of MCF-7 cells overexpressing P-gp; ↑ = increase; ↓ = decrease.
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Figure 1. A schema of different molecular mechanisms that are targeted by furanocoumarin. It shows 
several molecular singling pathways modulation that leads to autophagy, apoptosis, angiogenesis, 
and metastasis. Black lines: induce, and red lines: inhibit.
Figure 1. A schema of different molecular mechanisms that are targeted by furanocoumarin. It shows
several molecular singling pathways modulation that leads to autophagy, apoptosis, angiogenesis,
and metastasis. Black lines: induce, and red lines: inhibit.
3. Bioavailability of Furocoumarins
Furanocoumarins are rapidly absorbed from food into the human bloodstream and detected
in plasma within 2–15 min after administration [20], and distributed to the skin, blood, liver, brain,
spleen, kidney, and testis. In plasma, furanocoumarins bind to albumins and other plasma proteins.
Furanocoumarins are metabolized to psoralen and isopsoralen by intestinal bacteria in the digestive
tract. Then, furanocoumarins are excreted into urine as hydroxylated or glucuronated products within
1 h after ingestion. They remain in urine as long as 24 h post-administration. It was also observed that
furanocoumarins are converted to bergaptol before excretion [11,21,22].
A significant advance in the investigation of the anticancer properties of furanocoumarins was the
revelation of their antiproliferative activity arresting cell-cycle capture and causing cell death [23–25].




NF-κB and STAT3 inactivation or inhibition cause apoptosis and consequent ineffectiveness of
anticancer treatments [23,24]. NF-κB and signal transducer and activator of transcription 3 (STAT3)
association triggers inflammation and cancer [25]. Bergamottin enhances tumor necrosis factor (TNF)
induced apoptosis in U87 and U251 via NF-κB and STAT3 inhibition [26]. The blocking of NF-κB
activity by psoralen (80 µg/mL) leads to inhibition of FADD like IL-1β converting enzyme inhibitory
protein (c-FLIP) and inhibitor of apoptosis proteins (IAP), activation of Bax, JNKs, and blocking G1/S
phase in KBv200 and K562 [27].
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MMP-2,9 decrement, E-cadherin increment, EMT inhibition, and JNK cascade activation are
associated with NF-κB inactivation and result in antimetastatic behavior [28–32]. Angelicin inhibits
A549 non-small-cell lung carcinoma (NSCLC) growth and metastasis by reducing MMP-2,9; increasing
E-cadherin expression levels and JNK, and ERK activation [33]. Bergamottin inhibited the migration
abilities of A549, H1299 [34]; HT-1080 cells [35] and human fibrosarcoma HT-1080 cells [36],
by decreasing the phorbol 12-myristate 13-acetate (PMA)-initiated enactment of matrix metallo
proteinase (MMP)-2,9; c-jun N-terminal kinase (JNK) phosphorylation and EMT inhibition through
NF-κB inactivation. Psoralen give similar response in MCF-7/ADR cells [37]. Rac1 blocks drug-induced
apoptosis by maintaining Bad in the phosphorylated state [38]. Inactivation of Rac 1 is also responsible
for NF-κB inactivation [39]. Bergamottin exhibits antimetastatic behavior in U87 and U251 human
glioma cells through Rac1 inactivation and MMP-9 downregulation [26].
In chronic inflammation, immune cells generate excessive ROS and RNS in the inflamed tissue and
reinforce the NF-κB mediated inflammatory responses that can lead to tumorigenesis. Therefore, NF-κB
down regulation is helpful in cancer prevention and treatment by exerting anti-inflammatory effect [40,41].
NF-κB expresses cytokines, chemokines, and also maintains the inflammatory response through
persistent leukocyte activation [42,43]. Sphondin inhibits IL-1β-initiated-COX-2 by NF-κB inactivation
in the A549 cell line [44]. Imperatorin reduced IL-6, -1β, and TNF-α discharge and inhibited iNOS
and COX-2 by repressing NF-κB in RAW 264.7 (murine-macrophages-cell lines) [45,46]. Bergamottin,
Bergapten and Psoralen inhibit ROS/NO generation for anti-inflammatory activity [35,47,48].
4.2. PI3K/Akt Inhibition
Activated PI3K/Akt contributes to (i) protection of cells from apoptosis, by inactivation of Bax, Bad,
Bak, Bid, MDM2, caspase-9, and Bax and causes activation of cyclic AMP responsive element binding
protein (CREB) to induce transcription of Bcl-2, (ii) regulation of cell metabolism; (iii) fatty acid synthesis.
In apoptosis, cytosol Bax releases caspase-activating Cyt-c. The caspase-8 (extrinsic apoptosis) or -9
(intrinsic apoptosis), is activated which further activates caspase-3, essential to propagates apoptotic
signal [49–53]. Cell shrinkage and chromatin condensation helps in apoptosis [54]. Activated caspase-3
stimulates inhibitor of caspase activated DNAse (ICAD) to release caspase-activated DNAse (CAD),
which condenses the chromatin [55]. Angelicin in PC-3 cells [56] and bergamottin in A549 (NSCLC) cell
lines [57] cause chromatin condensation. Imperatorin induced selective antitumor effects in SGC-7901
cells without causing too much cytotoxicity to the normal mouse fibroblast cells (3T3 cells). It also
induced apoptosis, G1 phase arrest, DNA fragmentation, and downregulation of PI3K/Akt/m-TOR
signaling pathway [58]. Methoxsalen (8-MOP) activated caspase-8 -9, Bax/Bcl-2 ratio upregulation,
cytochrome-c (Cyt-c) release, and CREB phosphorylation decrement to down-regulates Bcl-2 for
apoptosis in SW620 and SK-N-AS cells, through PI3K/Akt down-regulation [51]. Angelicin increases
Bax, caspase-3, -9, decreases Bcl-2, Bcl-xL, Mcl-1 in A549 (NSCLC) cells [33], and SH-SY5Y cells [59]
to induce intrinsic mitochondria-mediated apoptosis. Angelicin, and in combination, activated
caspase-3 and decreased FADD like IL-1β converting enzyme inhibitory protein (c-FLIP) in Caki
(renal carcinoma) cells to induce apoptosis [60]. Bergamottin induces apoptosis in human colon
carcinoma cell line (RKO) and HT-29 cells by increasing caspase-3, 8, and 9; and PARP cleavage [61].
Bergapten inhibits breast cancer cell line (MCF-7) growth [62] and CRC cell viability [63] via inhibition
of Akt. Bergaptol inducesMCF-7 cytotoxicity by the same mechanism [64]. Methoxsalen (8-MOP)
inducesHepG2 cells apoptosis by Bax/Bcl-2 increment, MMPs decrement, and Cyt-c release and AIF
transposition induction [65]. Imperatorinin duce’s both intrinsic and extrinsic apoptotic pathways
by Bcl-2 protein expression downregulation, caspase-3, -7, -8, -9 activation, releases mitochondrial
Cyt-c to the cytosol and cleaves poly (ADP-ribose) polymerase (PARP) in HT-29, HL-60 [52,66],
SNU 449, HCT-15 [67], and HepG2 cells [68]. Isoimperatorin induces the apoptosis in SGC-7901 and
in vivo xenograft model by Bax, caspase-3, -9 increment, and Survivin and Bcl-2 decrement in nude
mice [69]. Marmesin inhibits colony formation and induces apoptosis in U937 cells by triggering
Bax upregulation, Bcl-2 downregulation, and Bax/Bcl-2 ratio increment [70]. Byakangelicol, cnidicin,
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imperatorin, isoimperatorin, oxypeucedanin and (+)-oxypeucedanin hydrate from Angelica dahurica
roots exert cytotoxicity in A549, HCT-15, SK-OV-3, SK-MEL-2, XF498 cells by similar mechanisms [71].
5-geranyloxy-7-methoxycoumarin from lime suppressesSW480 cell proliferation by apoptosis through
caspase-3, -8 activation, regulation of Bcl2, and p38 MAPK phosphorylation inhibition [72]. Psoralen
causes Bax increment and attenuates Bcl-2 expression in SMMC7721 human hepatoma cells [73]. Liver X
receptor (LXR) regulates lipid metabolism, inflammation and induces apoptosis through caspase-3
activation [74]. LXRs activation increases ABCA1 cholesterol transporters and inducible degrader
of the low-density lipoprotein receptor (IDOL) in turn triggering low-density lipoprotein receptor
(LDLR) degradation and reducing intracellular cholesterol, thereby reducing SREBPs, tumor growth,
and survival. Highly expressed SREBPs play important roles in malignancies, connecting oncogenic
signaling to lipid metabolism alterations, leading to rapid tumor growth. PI3K-Akt pathway is
inhibited by LXRs [53,75]. Bergapten inhibits liver carcinogenesis (HepG2) by activating LXRs,
inhibiting PI3K/Akt that reduced SREBP-1, fatty acid synthase (FASN), stearoyl-CoA desaturase-1
(SCD1), thereby preventing fatty acid synthesis and tumor growth [53].
The antitumor effects of angelicin involves decreased expression of p-VEGFR2 and PI3K/Akt
signaling inhibition in HepG2 and Huh-7 cells. In the same study, angelicin was shown to decrease
p-VEGFR in mouse liver orthotopic xenograft model [17]. Bergamottin suppresses TGF-β initiated
EMT and the cell invasive potential by PI3K, Akt, and mTOR kinases [35].
4.3. p53 Modulation
The p53 controls cell cycle progression and regulates apoptosis and autophagy [76]. p53 activation
promotes p21 and p27 expression, which restrain cyclin E and Cdk2 activity, thereby cause cell cycle
phase arrest [77]. Bergapten increases p53 activity that induces p21 transcription, which, in turn,
inhibits G2/M phase in HepG2 cells [11]; triggers G1 arrest in A549, NCI H460 [78] and MCF-7 cells [62].
p53 protein intervenes in two major apoptotic pathways: an “extrinsic pathway” induced by death
receptors (TNF proteins such as DR4 and DR5) and an “intrinsic pathway” that regulates Family
Bcl-2 proteins [5]. Bergapten (30 and 50 µM) decreased CRC (colorectal cancer) cells’ viability by
apoptosis via upregulation of p53, p21, and PTEN [63]. Furanocoumarin A from Fructus liquidambaris
induces the apoptosis in A549 by increasing p53 [79]. Imperatorin significantly upregulates p53 and
p21, which subsequently results in Mcl-1 down-regulation and Bax up-regulation in H23 human lung
cancer cell [80] and HT 29 colon cancer cells [52] to inhibit their growth. Psoralen upregulates p21,
waf and p53 in cells SKBR-3 MCF-7 cells, causing apoptosis [81,82]. Similarly, 5-geranyloxy-7-methoxy
coumarin induces apoptosis in SW480 cells through the activation of tumor suppressor gene p53 [72].
Psoralen inhibits SMMC7721 cells (human hepatoma cell line) proliferation by ER stress induction
by apoptosis. During ER-stress, glucose regulatory protein 78 (GRP78), GRP94, protein kinase R-like
ER kinase (PERK), inositol requiring enzyme 1 (IRE1), and activating transcription factor-6 (ATF6),
growth arrest and DNA damage inducible protein 34 (GADD34), and ATF4 increment can promote C/E
B P homologous protein (CHOP) and high expression of CHOP, thereby inhibiting Bcl-2 and promoting
apoptosis [73].
Psoralen causes exosomes formation and secretion reduction through p53 and PPAR activation in
MCF-7/ADR cells, which showed its role against chemotherapy resistance in breast cancer [83].
The antioxidant functions of p53 protein also induces apoptosis and autophagy [5,84]. Imperatorin
increases p53, in turn, exerting antioxidant effects that may contribute to its anticancer effects [85,86].
4.4. Cell Cycle Arrest
Cell cycle progression or arrest is related to cyclin-A, -B1, -D1, -E1 and cyclin B1, cyclin E1,
Cdc2, Cdk2 and Wnt/β-catenin [87–89]. Angelicin suppresses proliferation of A549 cells; HeLa and
SiHa cells by promoting G2/M and G1/G0 phase arrest respectively by cyclin-B1, -E1 and Cdc2
downregulation [33,90].Bergamottin arrests HT-29, RKO and A549 (NSCLC) cells at G2/M by cyclin-A,
-B1 and Cdc2 depletion [57,61]. Bergapten (5-MOP) blocks G2/M phase in Hep-G2 with the inhibition
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of Cdk1 [91]. Bergapten (30 and 50 µM) instigated the G0/G1 and sub-G1 stage capture in CRC cells
by a decrease of cyclin E/Cdk2 [63]. Bergaptol arrests G1-phase in MCF-7 [64]; Imperatorin in HT 29
and SGC-7901 cells [52,58] and isoimperatorin in DU145 and SGC-790 cells by increasing Cip1/p21
and Kip1/p27 expression and disrupting Cdk4 kinase synthesis [69,92]. Marmesin captures G2/M and
cell migration in U937 [70]. Psoralen arrests at G1 phase in SMMC7721 by Cyclin-E1 reduction [73].
Psoralen arrests G0/G1 by deregulation of Wnt/β-catenin in MCF-7 [93].
4.5. Autophagy
Increase in autophagy results in cell growth inhibition and apoptosis [94,95]. Angelicin accumulated
microtubule-associated LC3B and upregulated Atg-3,7 and 12-5 in HeLa and SiHa cells [90]. PTEN is
downregulated to corneal tumors [96]. Bergapten exhibited autophagy in MCF-7 and ZR-75 by PTEN,
AMBRA, Beclin1, PI3KIII and, UVRAG up-regulation and LC3-II conversion [97]. Feroniellin-A from
Feroniella lucida roots initiates autophagy in A549 by LC3-II conversion; Beclin-1 and Atg-5 enhanced
expression [98].
4.6. Antioxidant
Oxidative stress is caused by ROS accumulation and high ROS concentration is demanded
by cancerous cells. Anticancer phytochemicals with antioxidants properties reduce developing
cancer risks [45,99]. Bergamottin, bergaptol, methoxsalen [100], bergapten [101], imperatorin [102],
oxypeucedanin [103] and psoralen [104] have been reported to possess antioxidant activities.
N-nitrosodiethylamine (NDEA) causes oxidative stress and responsible for the carcinogenic effect.
Bergapten has shown to possess anticancer potential in vivo against NDEA-induced liver cancer via
antioxidant effects [53]. Hypoxia is a noteworthy component of tumor malignant growth, and it activates
hypoxia inducible factor (HIF), thus increasing tumor survival and proliferation [85]. Antioxidants
inhibit HIF-1 α activity by scavenging free radicals [105]. Imperatorin has been shown to inhibitHIF-1
in HCT116 due to its antioxidant behavior and mTOR/p70S6K/4E-BP1 and MAPK downregulation [86].
5. Role in MDR Cancers
Cancer cell defiance to chemotherapy is one of the significant deterrents for counter cancer
medications due to the involvement of different mechanisms. The main causes are related to the
increment of multidrug efflux pumps, including P-gp by tumor cells, and showed MDR. Coumarins
have a significant role in MDR inversion [106–108].
Psoralen inverts the P-gp-instigated MDR in MCF-7/ADR by repressing the efflux capacity of P
gp [108] and by hindrance of P-gp ATPase activity [37]. Similarly, isopimpinellin (IC50 value 26 µM)
and Phellopterin (IC50 value 8 µM) exhibited cytotoxic activity against MDR HL-60/MX2 (human
promyelocytic leukemia cells) and CEM/C1 (human lymphoblastic leukemia cells) respectively [109].
Feroniellin A reduces MDR in A549 cell lines by decreasing P-gp [98]. MDR1rapidly pumps out
anticancer drugs, decreases intracellular drug concentrations and leads to the failure of anticancer
therapeutics [110]. Similarly, BCRP and MRP overexpression participates in MDR [111,112]. Bergapten
and methoxsalen showed cytotoxicity in MDR1, MRP2 BCRP overexpressing gastric (EPG85.257RDB),
ovarian (A2780RCIS) and breast (MCF7MX) cancer cell lines which showed reticence of MDR1, BCRP,
and MRP efflux functions [113].
ETRα positive and estrogen dependence are seen in 70% of breast cancers. ETRα depletion during
initial stages of breast cancer is a potent anticancer approach [114]. Xanthotoxol, bergapten, angelicin,
psoralen and isoimperatorin antagonized ETRα activity in MCF-7 cells with IC50 values of 0.72, 1.18,
11.02, 24.08 and 54.32 µM, respectively [115].
Exosomes, secreted from tumor cells to promote tumor progression, such as metastasis and MDR,
activate sequestration of anticancer drugs by MDR-1 and P-gp [116]. Psoralen significantly reduces
the number of exosomes, which correlates with increased MCF-7/ADR cells’ sensitivity for apoptosis
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under the influence of chemotherapy. Similar observations were seen in A 549/D16 lung cancer cell
lines [11,83,117].
6. Furanocoumarins as Adjuvant with Other Anticancer Agents
Invasion and angiogenesis are important targets of FC (Figure 2). In a study, given that bergamottin
(50µM)-potentiated simvastatin (SV) inhibits TNF-induced NF-κB activation and IκBα deterioration,
cell-cycle capture in S-phase by boost of p21 and p27 in KBM-5 cells. This impact of co-treatment is
associated with decrease incyclin D1 (cell proliferation), Bcl-2, cIAP-1, Bcl-xL and survivin (cell survival),
MMP-9 (invasion), and VEGF (angiogenesis) which are directed by NF-κB. CYP P450 34A inhibition
by bergamottin enhances SV bioavailability in KBM-5 to synergize SV effects [35,118].Cytochrome
P450 upregulation in cancer makes it one of the effective strategy against it. CYP P450 inhibition
by furanocoumarins and other phytoconstituents leads to anticarcinogenic effects, down regulating
MDR and prolonging the t1/2 of other anticancer drugs [119,120]. Bergamottin, DHBG, bergapten,
and bergaptol inhibit CYP P450 34A to potentiate vinblastine effects [121]. Bergamottin, imperatorin,
and isopimpinellin repressed CYP P450-1A1, -1A2, -3A4, and -1B1 (involve in carcinogen metabolism),
in the MCF-7 cell lines [122]. MDR has been linked to BCRP, MRP, and MDR1 increase that expel
cisplatin, daunorubicin, and mitoxantrone are very common in cancer therapeutics [113]. Bergapten
and methoxsalen are capable of averting mitoxantrone, cisplatin, and daunorubicin binding to MDR1,
BCRP, and MRP and, therefore, impeding their cellular efflux [113]. Bergamottin, DHBG, bergapten,
and bergaptol from grapefruit juice inhibit P-gp and MRP2 mediated vinblastine efflux [121]. Long-term
use of tamoxifen in breast cancer leads to MDR and an increased risk of endometrial carcinogenesis [123].
Bergapten degrades and depletes ETRα from MCF-7 tamoxifen-resistant cells by inducing SMAD4
protein to block mitogenic signals [62]. The anticancer effects of doxorubicin in HeLa cells are enhanced
by Imperatorin via Mcl-1 down-regulation [124]. Imperatorin (100µM) effectively increasing autophagy
in HeLa cells in response to cisplatin (2 µM) by microtubule-associated protein 1A/1B-light chain 3
(LC3) cleavage and the inhibition of Hsp27 and Hsp72 [125]. Imperatorin potentiates the cytotoxicity
of cisplatin in hepatocellular carcinoma (HCC) cells (HepG2, HepG3B, PLC, Huh7) by downregulating
Mcl-1 expression [126].
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7. Furanocoumarins and Cancer Risks
PUVA therapy (photoactivated psoralens) is beneficial for patients with vitiligo, psoriasis,
and skin diseases. PUVA activates caspase-3, -8 and -9 in Jurkat (human tumor T-cell line) [127].
PUVA, the photoactivated psoralens (5-MOP and 8-MOP) induce apoptosis in MCF-7, ZR-75 and
SKBR-3 by caspase and p53 upregulation, PI3K/AKT downregulation and effective against breast
hormone-responsive cancers [128]. PUVA arrest G2/M phase by phospho-Chk1 increment and
phospho-Cdc2 decrement in B16F10 murine melanoma cell line [129]. Unfortunately, it is linked toa
risk of basal cell, squamous cell, and non-melanoma skin cancers [130,131]. PUVA has been approved
by the FD, [132]. PUVA is ideal for superficial applications only, due to low penetration into deep
tissues. Therefore, X-PACT has been introduced, which at low X-ray doses photoactivates psoralens
and hence mitigates the low penetration problem and adverse effects of PUVA [133].
8. Conclusions
Chemotherapy and radiation are the staples for treatment of malignant growth, however, both have
serious adverse health symptoms. It is known that tumors have developed many mechanisms at the
molecular level enabling cell survival during chemotherapy. Therefore, it is essential to develop novel
pharmaceuticals with increased efficacy and reduced toxicity. This review highlights the potential
for furanocoumarins to be clinically beneficial in cancer, particularly given their specificity to tumor
cells (while sparing normal cells). In vitro investigations have shown that furanocoumarins affect a
range of cellular mechanisms, such as apoptosis, autophagy, and cell cycle arrest. ER stress induction
mainly caused by NF-κB inactivation, PI3K/Akt inhibition, and p53 modulation. Furanocoumarins
are also effective in different MDR cancers that are the main cause of anticancer therapeutics failure.
Compounds in this class have also have been shown to positively synergize with commonly used
anticancer drugs. The fast absorption of furanocoumarins from food into the human bloodstream is also
noteworthy [134]. Furanocoumarins, by inhibiting CYP P450 3A4, not only have anticancer properties
but also when co-administered with a low bioavailability anticancer compound can increase oral
bioavailability [135]. Thus, as to improve genuine treatments for various sorts of tumors, nanomedicine
has developed new strategies coordinated to build the efficacy of medications focusing on tumors and
limit their side effects [136,137]. Furanocoumarin-loaded lipid-polymer-hybrid-nanoparticles represent
an additional option for sustained release of these molecules to improve efficacy and synergistic effects
with other anticancer agents and against MDR cancers [108,138,139]. To date, most focus has been on
in vitro studies, making it hard to reach solid conclusions on the efficacy of furanocoumarins in vivo.
Nonetheless, studies aimed at characterizing furanocoumarin’s efficacy in vivo as well as clinical
studies are encouraging, supporting the need for future studies to better characterize furanocoumarin’s
potential as efficacious anticancer treatment modalities.
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